-
In-depth analysis of key points of entrusted production management in "Cosmetics Production Quality Management Standard"
Time of Update: 2022-08-11
The "Specifications" separately set up the "Entrusted Production Management" chapter, which puts forward requirements for the main conditions of the cosmetics registrant and filing party (hereinafter referred to as the entrusting party), the management of the entrusted production enterprises, and the establishment and implementation of the management system .
-
Alarm bells!
Time of Update: 2022-08-11
Click to enter the exhibition pageRecently, there have been news of a large number of pharmacies being fined for publishing false advertisements, circumventing normal sales channels, selling prescription drugs without prescriptions, and not issuing sales vouchers, etc.
-
Blockbuster small molecule drugs officially announced the new crown treatment potential from 1 to 2 to take the new blue ocean
Time of Update: 2022-08-11
In this race against the new crown, another innovative pharmaceutical company, Ascentage Pharma (6855. HK), came to an end, bringing fresh blood and a turning point to this protracted battle . Because
-
The State Pharmacopoeia Commission began to solicit proposals for the 2023 national drug standard improvement project
Time of Update: 2022-08-11
affixed with the official seal, personal signature is required) and the electronic version of the materials will be fed back to our commission All relevant units are requested to focus on the compilation of the 2025 edition of the "Chinese Pharmacopoeia", put forward proposals for project establishment, and fill in the "2023 National Drug Standard Improvement Project Proposal Form" (see attachment), and submit the paper materials (units need to be required) before June 20, 2022.
-
Focus on anti-tumor and nervous system drugs, what are the FDA-approved drugs in the first quarter?
Time of Update: 2022-08-11
Table 1: FDA-approved BLA biologics in the first quarter of 2022 Data source: China Pharmaceutical Industry Information Center, Pharma ONE intelligent drug big data analysis platform Approved original chemical drug Among the 35 approved NDA drugs, 6 Type1-new molecular entity new drugs are worthy of attention, including 3 anti-tumor and immunomodulatory agents: Vonjo (pairitinib) is an inhibitor of JAK2, IRAK1 and CSF1R.
-
Can Luzsana become Hengrui's "Genentech"?
Time of Update: 2022-08-11
More than 250 clinical studies in each therapeutic area for global co-development and commercialization It is understood that through the partnership with the parent company Hengrui Medicine, Luzsana can evaluate and select assets from Hengrui's existing rich pipeline, covering oncology, cardiovascular, metabolism/diabetes, pain management, immunity, liver and kidney diseases, etc.
-
The Science and Technology Biopharmaceutical Index was released, and 8 pharmaceutical companies in Jiangsu were on the list
Time of Update: 2022-08-11
According to the data, in 2021, Nuotai Bio will achieve an operating income of 644 million yuan, a year-on-year increase of 13.
According to the data, in 2021, Nuotai Bio will achieve an operating income of 644 million yuan, a year-on-year increase of 13.
-
The National Medical Insurance Administration issued a notice that the new coronavirus nucleic acid test and antigen test will further reduce the price
Time of Update: 2022-08-11
Today, the National Medical Insurance Administration issued the "Notice of the Medical Rescue Team of the Joint Prevention and Control Mechanism of the New Coronavirus Pneumonia Epidemic by the Offic
-
101 new items added!
Time of Update: 2022-08-11
. Article 31 [General requirements for the evaluation of traditional Chinese medicines] The drug regulatory department of the State Council shall meet the major strategic needs of the country and the needs of people's life and health, follow the laws of traditional Chinese medicine research and development, scientifically and rationally set the technical requirements for traditional Chinese medicine evaluation, establish traditional Chinese medicine theory, traditional Chinese medicine human use A review evidence system combining experience and clinical trials .
-
The number of innovative drugs approved has reached a new high, and domestic independent research and development has entered the harvest period
Time of Update: 2022-08-11
Driven by multiple advantages such as policies, capital, and talents, the pace of domestic innovative drug listings has been accelerating With the continuous improvement of the innovation strength of local pharmaceutical companies, China's contribution to global pharmaceutical innovation is also increasing.
-
Announcement of the first batch of national drug standards for traditional Chinese medicine formula granules
Time of Update: 2022-08-11
. In order to ensure the scientificity, rationality and applicability of the standards, opinions from all walks of life are solicited on the publicity of the national drug standards for the above-mentioned traditional Chinese medicine formula granules (see the annex for details) .
-
Domestic pharmaceutical companies and multinational pharmaceutical companies are racing on two opposite tracks
Time of Update: 2022-08-11
Don't you see, large multinational pharmaceutical companies, mainly Pfizer and Sanofi, have "abandoned their soldiers to protect their leaders", throwing away product pipelines such as consumption, health care, and generic drugs; domestic pharmaceutical companies, on the contrary, have branched into medical beauty, CXO, and diversified products.
-
The per capita annual salary of pharmaceutical companies in 2021 will exceed 160,000 yuan, and 4 companies will increase their salary by more than 100%
Time of Update: 2022-08-11
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 12.
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 12.
-
Mirati Announces Latest Results of KRAS Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Time of Update: 2022-08-11
Mirati Therapeutics announced positive results from a Phase 2 clinical trial of its KRAS G12C inhibitor adagrasib in patients with previously treated non-small cell lung cancer harboring a KRAS G12C mutation .
-
The enthusiasm for ADC drug development is high, and another pharmaceutical company ADC innovative drug has been granted priority review qualification by the FDA
Time of Update: 2022-08-11
Huadong Medicine stated that Mirvetuximab Soravtansine is a FRα-targeted ADC drug, and it is also a key product under development in the company's innovative tumor drug pipeline .
-
The supervision of the retail pharmacy market is becoming more and more strict, and compliance has become a top priority
Time of Update: 2022-08-11
Recently, the National Medical Insurance Bureau exposed 10 typical cases of illegal violations by designated retail pharmacies, including the sale of non-medical insurance drugs or other commodities f
-
The net profit of 5 pharmaceutical companies in the first quarter of 2022 entered the "1 billion club" for the first time
Time of Update: 2022-08-11
Click to enter the exhibition pageRecently, while listed companies have disclosed their 2021 annual reports, their performance in the first quarter of 2022 has also been gradually announced .
-
In-depth analysis of the procurement volume of the two major alliances, centralized procurement forces the rational admission of traditional Chinese medicine imitation
Time of Update: 2022-08-11
New entrants cut prices for the market It can be seen from the centralized procurement rules of the Hubei Regional Alliance and the Guangdong Regional Alliance for the centralized procurement of Chinese patent medicines that if the generic varieties of traditional Chinese medicines want to compete for the market, it is difficult to obtain the procurement volume of medical institutions at the beginning .
-
Reflections on the change management of pharmaceutical excipients and pharmaceutical packaging materials under the related review policy
Time of Update: 2022-08-11
Summary OBJECTIVE: To provide reference for the implementation of the change management system for pharmaceutical excipients and pharmaceutical packaging materials under China's related review and ap
-
CDE Announcement on Issuing the "General Format and Guidelines for Writing Instructions for Chemical Drugs and Biological Products" (No. 28 of 2022)
Time of Update: 2022-08-11
Notice of the Center for Drug Evaluation of the State Food and Drug Administration on Issuing the "General Format and Writing Guidelines for the Instructions of Chemical Drugs and Biological Products
